| What is the actual prevalence of migraine? WZ Yeh, L Blizzard, BV Taylor Brain and behavior 8 (6), e00950, 2018 | 193 | 2018 |
| Multifocal motor neuropathy: controversies and priorities WZ Yeh, PJB Dyck, LH van den Berg, MC Kiernan, BV Taylor Journal of Neurology, Neurosurgery & Psychiatry, 2019 | 92 | 2019 |
| Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis WZ Yeh, PA Widyastuti, A Van der Walt, J Stankovich, E Havrdova, ... Neurology 96 (24), e2989-e3002, 2021 | 61 | 2021 |
| Heterozygosity for the common perforin mutation, p. A91V, impairs the cytotoxicity of primary natural killer cells from healthy individuals IG House, K Thia, AJ Brennan, R Tothill, A Dobrovic, WZ Yeh, R Saffery, ... Immunology and cell biology 93 (6), 575-580, 2015 | 51 | 2015 |
| Immunoregulatory effects and therapeutic potential of vitamin D in multiple sclerosis WZ Yeh, M Gresle, V Jokubaitis, J Stankovich, A van der Walt, ... British Journal of Pharmacology 177 (18), 4113-4133, 2020 | 30 | 2020 |
| MSCOVID19: Using social media to achieve rapid dissemination of health information C Nesbitt, L Rath, WZ Yeh, M Zhong, R Wesselingh, M Monif, J Richards, ... Multiple sclerosis and related disorders 45, 102338, 2020 | 24 | 2020 |
| Prediction of multiple sclerosis outcomes when switching to ocrelizumab M Zhong, A van der Walt, J Stankovich, T Kalincik, K Buzzard, O Skibina, ... Multiple Sclerosis Journal 28 (6), 958-969, 2022 | 14 | 2022 |
| Failure of alemtuzumab therapy in three patients with MOG antibody associated disease SO Seneviratne, M Marriott, S Ramanathan, W Yeh, F Brilot-Turville, ... BMC neurology 22 (1), 84, 2022 | 7 | 2022 |
| Neutropaenia complications from Ocrelizumab and Rituximab treatment V Pang, N Seery, R Wesselingh, W Yeh, M Zhong, T Tan, C Dwyer, ... Multiple Sclerosis and Related Disorders 81, 105147, 2024 | 6 | 2024 |
| Parity is associated with long-term differences in DNA methylation at genes related to neural plasticity in multiple sclerosis MP Campagna, A Xavier, J Stankovich, VE Maltby, M Slee, WZ Yeh, ... Clinical epigenetics 15 (1), 20, 2023 | 6 | 2023 |
| Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60 YC Foong, D Merlo, M Gresle, K Buzzard, M Zhong, WZ Yeh, V Jokubaitis, ... Journal of Neurology, Neurosurgery & Psychiatry, 2024 | 5 | 2024 |
| Transcriptomics identifies blunted immunomodulatory effects of vitamin D in people with multiple sclerosis WZ Yeh, R Lea, J Stankovich, S Sampangi, L Laverick, A Van der Walt, ... Scientific Reports 14 (1), 1436, 2024 | 5 | 2024 |
| Patient Preferences for Time and Location of Infusible Therapies in Multiple Sclerosis and Neuroimmunologic Disorders L Rath, MP Campagna, J Stankovich, J Ellis, V Jokubaitis, D McCarthy, ... International Journal of MS Care 23 (3), 114-118, 2021 | 5 | 2021 |
| Lymphoma, a great imitator in neurology WZ Yeh, S Muthusamy, P McKelvie, S Collins, A French, R Filshie, ... Journal of Clinical Neuroscience 73, 308-310, 2020 | 5 | 2020 |
| Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse BP Trewin, RC Dale, J Qiu, M Chu, N Jeyakumar, FD Cruz, J Andersen, ... Journal of Neurology, Neurosurgery & Psychiatry, 2024 | 4 | 2024 |
| Vaccinations in patients with multiple sclerosis: review and recommendations C Nesbitt, L Rath, M Zhong, AC Cheng, H Butzkueven, R Wesselingh, ... Medical Journal of Australia 214 (8), 350-354. e1, 2021 | 3 | 2021 |
| The clinical relevance of MOG antibody testing in cerebrospinal fluid M Reynolds, I Tan, K Nguyen, V Merheb, FXZ Lee, BP Trewin, M Lerch, ... Annals of Clinical and Translational Neurology, 2024 | 2 | 2024 |
| Prevalence of progression independent of relapse activity and relapse-associated worsening in patients with AQP4-IgG–positive NMOSD P Siriratnam, S Huda, A Van Der Walt, PG Sanfilippo, S Sharmin, ... Neurology 103 (12), e209940, 2024 | 1 | 2024 |
| Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies WZ Yeh, A Van Der Walt, OG Skibina, T Kalincik, R Alroughani, ... Neurology: Neuroimmunology & Neuroinflammation 11 (6), e200328, 2024 | 1 | 2024 |
| Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study P Siriratnam, P Sanfilippo, A van der Walt, S Sharmin, YC Foong, WZ Yeh, ... Journal of Neurology, Neurosurgery & Psychiatry, 2024 | 1 | 2024 |
Anneke Van Der WaltAssociate Professor, Central Clinical School, Monash University在 monash.edu 的电子邮件经过验证
